联合节拍化疗在体外增强[177Lu]Lu-DOTA-TATE的治疗效果
本研究在体外评估羟基脲、吉西他滨或曲沙他滨预处理对[177Lu]Lu-DOTA-TATE在SSTR2A高表达U2OS细胞及中表达BON1细胞中摄取与代谢活性的影响。结果显示三种化疗药均增加SSTR2A表达、细胞体积和[177Lu]Lu-DOTA-TATE摄取,并较单药治疗降低细胞代谢活性。
要点
- 羟基脲、吉西他滨和曲沙他滨均增加U2OS+SSTR2A细胞对[177Lu]Lu-DOTA-TATE的摄取。
- 三种化疗药均增加U2OS+SSTR2A和BON1+SSTR2A细胞的SSTR2A表达与细胞体积。
- 羟基脲预处理使U2OS+SSTR2A细胞经[177Lu]Lu-DOTA-TATE后的活力从59.5±22.3%降至18.8±5.2%。
核心结论
- 羟基脲、吉西他滨和曲沙他滨均增加U2OS+SSTR2A细胞的细胞体积、SSTR2A表达和[177Lu]Lu-DOTA-TATE摄取,同时较[177Lu]Lu-DOTA-TATE单药治疗降低细胞代谢活力。
- 进一步研究可能改变患者诊疗并改善接受[177Lu]Lu-DOTA-TATE治疗患者的结局。
研究设计与样本
- 体外研究:转染人骨肉瘤细胞(U2OS+SSTR2A,SSTR2A高表达)和胰腺神经内分泌肿瘤细胞(BON1+STTR2A,SSTR2A中表达)先以羟基脲、吉西他滨或曲沙他滨处理24小时(37℃、5%CO2),恢复4小时后与0.7-1.03 MBq [177Lu]Lu-DOTA-TATE(25 nM)孵育24小时。
主要发现
- U2OS+SSTR2A细胞经羟基脲、吉西他滨和曲沙他滨处理后,[177Lu]Lu-DOTA-TATE摄取分别从untreated细胞的0.2±0.1 Bq/cell增至0.4±0.1、1.1±0.2和0.9±0.2 Bq/cell。
- U2OS+SSTR2A细胞经羟基脲预处理后,[177Lu]Lu-DOTA-TATE治疗后的活力从59.5±22.3%降至18.8±5.2%。
- 对照条件未显示代谢活力降低。
- 化疗药增加U2OS+SSTR2A和BON1+STTR2A细胞的SSTR2A表达和细胞体积。
- 异步U2OS+SSTR2A细胞培养的S期亚群经羟基脲、吉西他滨和曲沙他滨处理后分别从45.5±3.3%增至84.8±2.5%、85.9±1.9%和86.6±2.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究(Further investigations could transform patient care and positively increase outcomes)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peptide receptor radionuclide therapy (PRRT) uses [177Lu]Lu-[DOTA0-Tyr3]octreotate ([177Lu]Lu-DOTA-TATE) to treat patients with neuroendocrine tumours (NETs) overexpressing the somatostatin receptor 2A (SSTR2A). It has shown significant short-term improvements in survival and symptom alleviation, but there remains room for improvement. Here, we investigated whether combining [177Lu]Lu-DOTA-TATE with chemotherapeutics enhanced the in vitro therapeutic efficacy of [177Lu]Lu-DOTA-TATE. RESULTS: Transfected human osteosarcoma (U2OS + SSTR2A, high SSTR2A expression) and pancreatic NET (BON1 + STTR2A, medium SSTR2A expression) cells were subjected to hydroxyurea, gemcitabine or triapine for 24 h at 37oC and 5% CO2. Cells were then recovered for 4 h prior to a 24-hour incubation with 0.7-1.03 MBq [177Lu]Lu-DOTA-TATE (25 nM) for uptake and metabolic viability studies. Incubation of U2OS + SSTR2A cells with hydroxyurea, gemcitabine, and triapine enhanced uptake of [177Lu]Lu-DOTA-TATE from 0.2 ± 0.1 in untreated cells to 0.4 ± 0.1, 1.1 ± 0.2, and 0.9 ± 0.2 Bq/cell in U2OS + SSTR2A cells, respectively. Cell viability post treatment with [177Lu]Lu-DOTA-TATE in cells pre-treated with chemotherapeutics was decreased compared to cells treated with [177Lu]Lu-DOTA-TATE monotherapy. For example, the viability of U2OS + SSTR2A cells incubated with [177Lu]Lu-DOTA-TATE decreased from 59.5 ± 22.3% to 18.8 ± 5.2% when pre-treated with hydroxyurea. Control conditions showed no reduced metabolic viability. Cells were also harvested to assess cell cycle progression, SSTR2A expression, and cell size by flow cytometry. Chemotherapeutics increased SSTR2A expression and cell size in U2OS + SSTR2A and BON1 + STTR2A cells. The S-phase sub-population of asynchronous U2OS + SSTR2A cell cultures was increased from 45.5 ± 3.3% to 84.8 ± 2.5%, 85.9 ± 1.9%, and 86.6 ± 2.2% when treated with hydroxyurea, gemcitabine, and triapine, respectively. CONCLUSIONS: Hydroxyurea, gemcitabine and triapine all increased cell size, SSTR2A expression, and [177Lu]Lu-DOTA-TATE uptake, whilst reducing cell metabolic viability in U2OS + SSTR2A cells when compared to [177Lu]Lu-DOTA-TATE monotherapy. Further investigations could transform patient care and positively increase outcomes for patients treated with [177Lu]Lu-DOTA-TATE.
引用
- Cheng J, Zink J, O'Neill E, et al. Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics. EJNMMI Res. 2024. PMID: 39136880. doi:10.1186/s13550-024-01135-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。